Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease

Paola Dongiovanni, Marica Meroni, Rosellina M. Mancina, Guido Baselli, Raffaela Rametta, Serena Pelusi, Ville Männistö, Anna L. Fracanzani, Sara Badiali, Luca Miele, Stefania Grimaudo, Salvatore Petta, Elisabetta Bugianesi, Giorgio Soardo, Silvia Fargion, Jussi Pihlajamäki, Stefano Romeo, Luca Valenti – 25 April 2018 – Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver damage and has a strong genetic component.

LiverLearning®: 2018 Webinar: Role of Diet and Exercise in the Management of NAFLD

In this webinar, we will review the role of diet and exercise in the management of NAFLD. Specifically, we will overview the data in support of specific nutritional programs and physical activity regimens that have been shown to improve histologic components of NAFLD and NASH. Lastly, we will outline the remaining knowledge gaps and barriers related to lifestyle interventions in the treatment of NAFLD/NASH.Michelle Long Michelle T.

Efficacy and Safety of Peginterferon Alfa‐2a (40KD) in Children With Chronic Hepatitis B: The PEG‐B‐ACTIVE Study

Stefan Wirth, Hongfei Zhang, Winita Hardikar, Kathleen B. Schwarz, Etienne Sokal, Weibo Yang, Huimin Fan, Vyacheslav Morozov, Qing Mao, Hong Deng, Yang Huang, Lei Yang, Nicolas Frey, Clare Nasmyth‐Miller, Vedran Pavlovic, Cynthia Wat – 24 April 2018 – Children with chronic hepatitis B (CHB) represent an area of unmet medical need, attributed to increased lifetime risk of CHB sequelae and limited therapeutic options compared with adult CHB patients. The PEG‐B‐ACTIVE (NCT01519960) phase III study evaluated peginterferon (PegIFN) alfa‐2a treatment in children aged 3 to <18 years with CHB.

Acute‐on‐Chronic Liver Failure: Getting Ready for Prime Time?

Jasmohan S. Bajaj, Richard Moreau, Patrick S Kamath, Hugo E. Vargas, Vicente Arroyo, K. Rajender Reddy, Gyongyi Szabo, Puneeta Tandon, Jody Olson, Constantine Karvellas, Thierry Gustot, Jennifer C. Lai, Florence Wong – 24 April 2018 – Acute on chronic liver failure (ACLF) is the culmination of chronic liver disease and extrahepatic organ failures, which is associated with a high short‐term mortality and immense health care expenditure. There are varying definitions for organ failures and ACLF in Europe, North America, and Asia.

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid

Angela C. Cheung, Aliya F. Gulamhusein, Brian D. Juran, Erik M. Schlicht, Bryan M. McCauley, Mariza de Andrade, Elizabeth J. Atkinson, Konstantinos N. Lazaridis – 24 April 2018 – The United Kingdom‐Primary Biliary Cholangitis (UK‐PBC) risk scores are a set of prognostic models that estimate the risk of end‐stage liver disease in patients with PBC at 5‐, 10‐ and 15‐year intervals. They have not been externally validated outside the United Kingdom.

Acute‐on‐Chronic Liver Failure: Getting Ready for Prime Time?

Jasmohan S. Bajaj, Richard Moreau, Patrick S Kamath, Hugo E. Vargas, Vicente Arroyo, K. Rajender Reddy, Gyongyi Szabo, Puneeta Tandon, Jody Olson, Constantine Karvellas, Thierry Gustot, Jennifer C. Lai, Florence Wong – 24 April 2018 – Acute on chronic liver failure (ACLF) is the culmination of chronic liver disease and extrahepatic organ failures, which is associated with a high short‐term mortality and immense health care expenditure. There are varying definitions for organ failures and ACLF in Europe, North America, and Asia.

Subscribe to